| Name | Title | Contact Details |
|---|
Dextra Partners specializes in unlocking access to middle market private equity investments
Software that makes offering professional services easy, scalable and profitable.
VOLT.ai is a company that provides cloud-based enterprise security solutions powered by AI. Their platform integrates with existing infrastructure for a proactive approach to incident management and response.
Circuit Path is a Los Angeles, CA-based company in the Software and Internet sector.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.